**Name of journal: *World Journal of Diabetes***

**ESPS Manuscript NO: 30973**

**Manuscript type: Orginal article**

***Clinical Trials Study***

**Association between dairy intake, lipids and vascular structure and function in diabetes**

Petersen KS *et al*. Dairy intake, lipids and vascular health

**Kristina S Petersen, Jennifer B Keogh, Natalie Lister, Jacquelyn M Weir, Peter J Meikle, Peter M Clifton**

**Kristina S Petersen, Jennifer B Keogh, Natalie Lister, Peter M Clifton,** School of Pharmacy and Medical Sciences and Sansom Institute for Health Research, University of South Australia, Adelaide, SA 5000, Australia

**Jacquelyn M Weir, Peter J Meikle,** Baker IDI Heart and Diabetes Institute, Melbourne, Victoria 3004, Australia

**Author contributions:** Petersen KS saw the volunteers, measured the physiological and dietary variables, analysed the data and wrote the first draft; Clifton PM and Keogh JB designed the study, analysed the data and drafted the manuscript; Lister N measured the physiological and dietary variables; Weir JM and Meikle PJ performed the lipidomics; all authors read and approved the final manuscript.

**Supported by** the Heart Foundation and the Government of South Australia, No. CR 12A 6750 to Keogh JB; NHMRC Principal Research Fellowship, No. APP1125691 to Clifton PM; NHMRC Senior Research Fellowship, No. APP1042095 to Meikle PJ; an Australian Postgraduate Award, No. 138093 to Petersen KS; and a University of South Australia Postgraduate Award, No. 128123 to Lister N.

**Institutional review board statement:** Ethics approval was obtained from the University of South Australian Human Research Ethics Committee.

**Clinical trial registration statement:** The trial was registered with the Australian New Zealand Clinical Trials Registry [www.anzctr.org.au/](http://www.anzctr.org.au/) (ACTRN12613000251729) on 4/09/2014.

**Informed consent statement:** All the participants provided written informed consent prior to study enrolment.

**Conflict-of-interest statement:** The authors declare that they have no competing interests.

**Data sharing statement:** Dataset available from the corresponding author at [Jennifer.keogh@unisa.edu.au](mailto:Jennifer.keogh@unisa.edu.au). Consent for data sharing was not obtained but the data is anonymised and risk of identification is very low.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Correspondence to: Dr. Jennifer B Keogh,** School of Pharmacy and Medical Sciences, University of South Australia, GPO Box 2471 Adelaide SA 5000, Australia. [jennifer.keogh@unisa.edu.au](mailto:jennifer.keogh@unisa.edu.au)

**Telephone:** +61-8-83022579

**Fax:** +61-8-83022389

**Received:** October 25, 2016

**Peer-review started:** October 28, 2016

**First decision:** December 1, 2016

**Revised:** December 15, 2016

**Accepted:** March 12, 2017

**Article in press:**

**Published online:**

**Abstract**

***AIM***

to determine lipid species that change in response to a change in dairy consumption. In addition, to investigate whether dairy associated lipid species are correlated with changes in measures of vascular structure and function.

***METHODS***

A 12-month randomised controlled trial was conducted to determine the effect of increased consumption of fruit, vegetables and dairy, compared to usual diet, on measures of vascular structure and function in adults with type 1 and type 2 diabetes (*n* = 108). This paper comprises post-hoc analyses investigating the relationship between dairy intake, serum lipid species and vascular health. Central and peripheral blood pressure, carotid femoral pulse wave velocity, augmentation index, serum lipid species and dietary intake were measured at baseline and 3-months. Common carotid artery intima media thickness was measured at baseline and 12-months.

***RESULTS***

serum lipid species [lysophosphatidylcholine (LPC) 14:0, LPC 15:0, LPC 16:1, phosphatidylcholine (PC) 29:0 PC 30:0, PC 31:0 and cholesterol ester (CE) 14:0] were associated with the change in full fat dairy consumption (rho 0.19-0.25; *p* < 0.05). The 3-month change in some lipids was positively associated with the 3-month change in central systolic [LPC 14:0 (rho 0.30; *p* = 0.007), PC 30:0 (rho 0.28; *p* = 0.010)] and diastolic blood pressure [LPC 14:0 (rho 0.32; *p* = 0.004), LPC 15:0 (rho 0.23; *p* = 0.04), LPC 16:1 (rho 0.23; *p* = 0.035), PC 29:0 (rho 0.28; *p* = 0.01), PC 30:0 (rho 0.36; p=0.001), PC 31:0 (rho 0.30; *p* = 0.007)] and 12-month change in common carotid artery intimal medial thickness [CE 14:0 (rho 0.22; *p* = 0.02)]. Pulse wave velocity and augmentation index were unrelated to dairy and lipid species.

***CONCLUSION***

an increase in dairy associated lipids appears to be associated with an increase in blood pressure and common carotid intimal medial thickness

**Key words:** lipidomics; lipids; phospholipids; atherosclerosis; dairy; lysophosphatidylcholine; carotid intima media thickness; pulse wave velocity; diabetes

**© The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** We have examined the relationship between changes in dairy intake, lipid species and vascular function. Although it was expected that an increase in dairy intake would lower blood pressure and be associated with improvements in vascular structure we found that increases in lipid species associated with dairy (LPC 14:0, LPC 15:0, LPC 16:1, CE 14:0) were associated with adverse changes in these parameters. Dairy does not appear to be beneficial in people with diabetes.

Petersen KS, Keogh JB, Lister N, Weir JM, Meikle PJ, Clifton PM. Association between dairy intake, lipids and vascular structure and function in diabetes. *World J Diabetes* 2017; In press

**Introduction**

By 2030 it is projected that 7.7% of the world’s population will have diabetes, which is an increase of 54% since 2010[[1](#_ENREF_1)]. Individuals with type 1 and type 2 diabetes are two-to-three times more likely to develop cardiovascular disease (CVD) compared with the general population[[2](#_ENREF_2), [3](#_ENREF_3) , [4](#_ENREF_4)]. In Australia, in 2010 approximately 30% of all deaths in people with type 1 and type 2 diabetes were due to CVD[[5](#_ENREF_5)]. Poor diet is the leading contributor to the global burden of disease[[6](#_ENREF_6)] and better dietary quality is associated with lower rates of CVD[[7](#_ENREF_7), [8](#_ENREF_8)]. The most recent evidence from prospective cohort studies suggests that dairy consumption is protective against CVD[[9](#_ENREF_9)]. Although uncertainty remains about the vascular effects of dairy fatty acids[[10](#_ENREF_10)].

Arterial stiffness measured by augmentation index and carotid femoral pulse wave velocity (cfPWV) are independent predictors of CVD[[11](#_ENREF_11), [12](#_ENREF_12)]. Similarly, carotid intima media thickness (IMT) is an early measure of atherosclerosis that predicts CVD[[13](#_ENREF_13), [14](#_ENREF_14)]. Epidemiological studies have indicated that higher consumption of dairy products is associated with lower carotid IMT[[15](#_ENREF_15), [16](#_ENREF_16)] and less arterial stiffening[[15](#_ENREF_15), [17-19](#_ENREF_17)].

Self-reported dietary intake is limited by inaccurate reporting which is well-documented in the general population and people with diabetes[[20](#_ENREF_20)]. Biomarkers of dietary intake, including dairy consumption, remove the reliance on self-reported dietary data. Previously it has been shown that fatty acids of ruminant origin are correlated with self-reported dietary intake of dairy products[[19](#_ENREF_19), [21](#_ENREF_21)].

The aim is to determine serum lipid species that change in response to a change in dairy consumption. Based on our previous analysis[[19](#_ENREF_19)] we hypothesise that the following lipid species will reflect a change in dairy consumption: cholesterol ester (CE) 14:0, CE 15:0, lysophosphatidylcholine (LPC) 14:0, LPC 15:0, LPC 17:1, phosphatidylcholine (PC) 29:0, PC30:0, PC31:0, PC31:1, PC33:0, PC33:1, PC33:3, PC35:0, sphingomyelin (SM) 31:1, SM32:0, triacylglycerol (TG) 16:0/16:0/16:0. The secondary aims are to determine the correlation between the change in dairy associated lipid species and 3-month change in peripheral and central blood pressure, augmentation index and cfPWV. The 12-month change in common carotid artery intima media thickness (CCA IMT) will also be correlated with the change in lipid species.

**Materials and methods**

***Study design***

As previously reported, a 12-month randomised controlled trial was conducted to determine the effect of improving dietary quality on CCA IMT, compared to a control group continuing on their habitual diet, in a cohort of people with type 1 and type 2 diabetes[[22](#_ENREF_22)]. Briefly, participants were randomised to increase consumption of fruit (+1 serve/day), vegetables (+2 serves/day) and dairy (+1 serve/day), regardless of usual intake or to continue on their usual diet. One serve of dairy was either 250 ml of milk or 200 g of yoghurt and no advice was given regarding the fat content. Dietary counselling was provided by a dietitian. Ethics approval was obtained from the University of South Australian Human Research Ethics Committee and the participants provided written informed consent. The trial was registered with the Australian New Zealand Clinical Trials Registry (ACTRN12613000251729) on 04/09/2014.

A post hoc analysis was conducted which comprised a subsample of the cohort (*n* = 108) that had serum lipidomic analysis performed at baseline and 3-months. A food frequency questionnaire (FFQ) was used to measure dietary intake at baseline and 3-months and a fasting serum sample was collected for measurement of lipid species. Participants had peripheral and central blood pressure, augmentation index and cfPWV measured at baseline and 3-months. In addition, CCA IMT was measured at baseline and 12-months. The intervention to increase dairy by one serve per day was only partially successful with 34 people in the intervention group increasing and 17 decreasing their dairy consumption, while in the control group 23 increased and 34 reduced their dairy intake. Thus overall 57 people increased and 51 decreased dairy intake so the analyses were performed without regard for allocation to intervention or control.

***Subjects***

Subjects above 18 years of age with diagnosed type 1 or type 2 diabetes for any duration managed with diet, oral hypoglycaemic agents (OHA) and/or insulin were recruited from August 2012 until December 2013 from a database of volunteers, public advertisements and a recruitment company (Intuito Market Research, Adelaide, South Australia). Exclusion criteria were: unstable CVD requiring active intervention, heart failure, significant renal impairment (eGFR < 30 ml/min), liver disease, cancer or allergic/intolerant/dislike of fruit, vegetables or dairy.

## ***Serum lipid analysis***

Lipid analysis was performed on fasting serum by liquid chromatography, electrospray ionization–tandem mass spectrometry as previously published[[23](#_ENREF_23)]. In total, 342 individual lipid species were measured from 23 classes.

## ***Food frequency questionnaire***

Habitual dietary intake was measured using the electronic version of the Dietary Questionnaire for Epidemiological Studies Version 2 FFQ. The FFQ includes questions on the types of milk (fat content), cheese (hard, firm, soft, ricotta, cottage cheese, cream cheese or low fat cheese) and spreads (butter) used. Questions about the quantity of milk consumed per day (none, < 250 ml, 250-500 ml, 500-750 ml, > 750 ml) and the frequency of cheese, yoghurt and ice-cream consumption are also included. This FFQ has been found to have relatively good agreement with a 3-day weighed food record in the general population[[24](#_ENREF_24)] and in people with type 1 and type 2 diabetes[[25](#_ENREF_25)].

## ***Measurements***

### Anthropometric measurements: Height was measured using a stadiometer (SECA, Hamburg, Germany) to the nearest 0.1cm while barefoot/flat footwear. Weight was measured to the nearest 0.05kg using calibrated electronic scales (SECA, Hamburg, Germany) while the participants were barefoot/light footwear and wore light clothing.

### **Peripheral blood pressure:** Clinic blood pressure was measured using an automated sphygmomanometer (SureSigns VS3; Philips, North Ryde, Sydney, Australia) once the participant had been seated for 5 min. A normal sleeve (16 cm × 52 cm) was used for an arm circumference of 24-32 cm and a large sleeve (16 cm × 70 cm) for an arm circumference of 32-42 cm. A minimum of four consecutive readings were taken at 1 minute intervals. The first reading was discarded and the following three consistent measurements i.e. systolic blood pressure within a range of 1.3 kPa, were used.

### **Common carotid artery intima media thickness:** The measurements of the carotid artery were taken using B mode ultra-sound by one operator, with an intra-observer coefficient of variation (CV) of 4.4% (*n* = 34). The participants were supine with their head positioned at 45 degrees away from the side of the neck being measured. A high resolution ultrasound machine with a 12MHz transducer was used (Samsung Medison MySono U6, South Korea). A 1cm region of the IMT on the far wall of the distal common carotid artery on both sides was measured using automatic edge detection software (Samsung Medison MySono U6 Auto IMT, South Korea) as recommended in the Mannheim Carotid Intima- Media Thickness Consensus Paper (2004-2006-2011)[[26](#_ENREF_26)]. Areas of plaque, defined as a 50% greater IMT than the surrounding IMT or IMT > 1.5 mm, were not imaged. Three 3 second clips were captured and the mean of 10 measurements taken from each of these clips was averaged for a mean and mean maximum CCA IMT value at baseline and 12 months.

### **Central blood pressure and augmentation index:** A SphygmoCor® XCEL (AtCor Medical, West Ryde, Sydney, Australia) was used to measure central blood pressure and augmentation index. A cuff was placed over the brachial artery on the right arm and measurements were completed after the participants had been quietly resting for 5 min. Three consecutive measurements were taken and the average calculated. All of the measurements were taken by one operator with a CV of 4.2% (*n* = 28).

### **Pulse wave velocity:** A SphygmoCor® XCEL (AtCor Medical, West Ryde, Sydney, Australia) was used to measure cfPWV. The tonometer was placed on the right carotid artery and the cuff on the right femoral artery. A 10-s recording of the carotid-femoral waveform was taken. Three measurements were performed at each time-point and an average taken. The measurements were taken by two operators; the intra-observer CVs were 4.2% (*n* = 28) and 7.3% (*n* = 11), respectively and the inter-observer CV was 5.0% (*n* = 18).

***Statistical analysis***

Data are presented as mean ± SD. The change in dairy intake between baseline and 3-months was not different between the groups so the cohort was analysed as a whole. Paired samples t- tests were used to determine the change in dairy intake, anthropometric measures, blood pressure, biochemistry and vascular measurements over time.

Change in lipid species containing fatty acids 15:0, 16:1 and 17:0 known to be of ruminant origin[[27-29](#_ENREF_27)] (CE 15:0, CE 16:1, CE 17:0, diacylglycerol (DG) 16:1/18:1, LPC 15:0, LPC 16:1, LPC 17:0, TG 15:0/18:1/16:0, TG 15:0/18:1/18:1, TG 16:1/16:1/16:1, TG 16:1/16:1/18:0, TG 16:1/16:1/18:1, TG 16:1/18:1/18:1, TG 16:1/18:1/18:2, TG 17:0/16:0/16:1, TG 17:0/16:0/18:0, TG 17:0/18:1/14:0, TG 17:0/18:1/16:0, TG 17:0/18:1/16:1, TG 17:0/18:1/18:1, TG 17:0/18:2/16:0) and those we have previously shown to be correlated with dairy consumption[[19](#_ENREF_19)] (CE 14:0, CE 15:0, LPC 14:0, LPC 15:0, LPC 17:1, PC 29:0, PC 30:0, PC 31:0, PC 31:1, PC 33:0, PC 33:1, PC 33:3, PC 35:0, SM 31:1, SM 32:0, TG 16:0/16:0/16:0) were correlated with the 3-month change in full fat dairy consumption. Spearman’s correlation was used to correlate the change in dairy consumption with the change in lipid species because the data did not have a normal distribution. Lipid species that were correlated with the change in full fat dairy consumption were correlated with the change in vascular measurements. Both absolute and percent change (change/baseline × 100) are presented. No adjustment for multiple testing were made with this analysis. Secondary analyses involving all of the lipid species (> 300) were conducted. Spearman’s correlation was used to determine the association between the change in lipid species and the change in vascular measures. In addition, baseline concentrations of the lipid species were correlated with the change in vascular measures. These secondary analyses were corrected for multiple comparisons using the Benjamini Hochberg approach[[30](#_ENREF_30)]. Analyses were performed using SPSS (version 19, 2010, SPSS Inc, Chicago, IL, United States). Statistical significance was set at *p* < 0.05. The statistical methods of this study were reviewed by Ms Kylie Lange from the University of Adelaide, Australia.

**Results**

A total of 108 participants were involved in these analyses, see Figure 1. Baseline characteristics of the participants included in this subsample were not different from non-participants with regards to age, weight, BMI, peripheral blood pressure, central systolic blood pressure, mean or mean maximum CCA IMT. Central diastolic blood pressure, augmentation index, cfPWV and HbA1c were higher (*p* < 0.05) in the non-participants compared with the participants. Baseline characteristics of the participants are presented in Table 1.

Table 2 shows consumption of dairy products measured using the FFQ. There was no significant change in total or full fat dairy consumption over time. Yoghurt consumption increased while cheese and butter consumption decreased. There was no effect of the treatment on dairy consumption or lipid levels, so we were able to examine the association between the change in dairy intake and the change in lipid species in the entire cohort to identify dairy associated lipid species. And we further analysed the correlation between the change in dairy associated lipid species and vascular measurements.

Table 3 shows the results of correlating the change in lipid species containing 15:0, 16:1 or 17:0 or those identified as correlating with dairy intake in the previous cross-sectional study with the change in full fat dairy consumption (milk, yoghurt, cheese, butter and ice-cream). No adjustments were made.

Table 4 shows the anthropometric measurements, blood pressure, biochemistry and vascular measurements at baseline and follow-up in the whole group. Measurements of central blood pressure and augmentation index were performed on 82 participants due to equipment availability. cfPWV was performed on 70 participants due to technical difficulties because of obesity. The lipid species that were shown to be correlated with total full fat dairy consumption (LPC 14:0, LPC 15:0, LPC 16:1, PC 29:0, PC 30:0, PC 31:0, CE 14:0) were then correlated with the vascular measurements that changed over time.

Table 5 presents the results of these analyses including both absolute and percent change in each parameter. Percent and absolute change in LPC 14:0, PC 30:0 and PC 31:0 were correlated with percent and absolute change in central systolic and diastolic blood pressure and central mean arterial pressure. Change in central diastolic blood pressure was correlated with the change in LPC 15:0, LPC 16:1, PC 29:0 and PC 31:0. Change in central mean arterial pressure was also correlated with the change in PC 31:0. The absolute and percent change in CCA IMT was correlated with the absolute and percent change in CE 14:0 only. There were no lipid species that were associated with the change in augmentation index or cfPWV. Change in full fat dairy consumption itself was not associated with the change in any of the vascular measurements. When the change in all of the lipid species (*n* > 300) was examined after correction for multiple comparisons, there were no significant correlations between any of the lipid species and the change in central systolic and diastolic blood pressure, central mean arterial pressure, augmentation index or CCA IMT

Baseline concentration of PC 34:4 (rho = -0.32; *p* < 0.0001), PC 32:2 (rho = -0.33; *p* < 0.0001), GM3 ganglioside (GM3) 16:0 (rho = -0.34; *p* < 0.0001), GM3 18:0 (rho = -0.38; *p* = 0.0001) and Total GM3 (rho = -0.36; *p* = 0.0003) were inversely associated with the change in CCA IMT, after adjustment for multiple comparisons. The change in central systolic and diastolic blood pressure, central mean arterial pressure, augmentation index or cfPWV were not associated with the concentration of any lipid species at baseline after correction for multiple comparisons.

**Discussion**

These analyses show that a change in the concentration of a number of serum lipid species (LPC 14:0, LPC 15:0, LPC 16:1, PC 29:0 PC 30:0, PC 31:0, CE 14:0), previously shown to be correlated with dairy consumption, were associated with a change in full fat dairy consumption in the present study. One or more of these lipid species were positively associated with the 3-month change in central blood pressure and 12-month change in CCA IMT in this cohort with type 1 and type 2 diabetes.

Fatty acids C15:0 and C17:0 are not produced endogenously and are constituents of dairy fat. The fatty acid C14:0 is produced endogenously but is also a component of dairy fat. Therefore these fatty acids in plasma or for C14:0 in adipose tissue are considered biomarkers of dairy intake[[28](#_ENREF_28)]. In the present study change in LPC 15:0, LPC 14:0 and CE 14:0 were weakly positively correlated with the change in consumption of full fat dairy. LPC concentration in milk fat is < 1% of the total PC concentration and therefore dairy would be an unlikely direct source of LPC species [[21](#_ENREF_21)]. LPC lipid species are predominately produced endogenously through a number of different processes including from PC by phospholipase A2 enzyme and the oxidation of LDL particles[[31](#_ENREF_31), [32](#_ENREF_32)].

In a randomised cross-over study, consumption of a full fat dairy diet containing non-fermented products (butter, cream or ice cream) was associated with higher plasma concentrations of sphingomyelin compared with low-fat dairy intake[[33](#_ENREF_33)]. Plasma concentrations of odd chain phosphatidylcholine (15:0 and 17:0) were increased with consumption of both full fat fermented (including yoghurt and cheese) and non-fermented dairy products. In this study vascular measurements were not performed. Previously we showed a cross-sectional association between serum lipid species and consumption of full fat dairy in people with type 1 and type 2 diabetes but serum lipid species were not associated with arterial stiffness despite dairy consumption being inversely associated with cfPWV[[19](#_ENREF_19)]. In addition, baseline CCA IMT was not associated with any serum lipid species. In the present study, changes in serum lipid species were associated with the change in central blood pressure (LPC 14:0, LPC 15:0, LPC 16:1, PC 29:0, PC 30:0, PC 31:0) and the change in CCA IMT (CE 14:0). In addition, baseline concentration of PC 34:4, PC 32:2, GM3 16:0, GM3 18:0 and total GM3 were associated with the change in CCA IMT such that higher baseline levels were associated with greater CCA IMT regression. GM3 accumulation has been observed in intimal atherosclerotic lesions in the carotid artery and aorta[[34](#_ENREF_34)] and serum GM3 has been identified as a potential marker of early atherosclerosis[[35](#_ENREF_35)]. Therefore this finding suggests that those with greater atherosclerotic burden at baseline had greater CCA IMT regression which is consistent with our previous finding[[22](#_ENREF_22)].

This study shows that when dairy associated serum lipids species were reduced at 3-months there was a reduction in central blood pressure and CCA IMT. Conversely when there was an increase in these serum lipid species central blood pressure increased. This finding is not consistent with previous research showing an inverse association between dairy consumption and blood pressure[[17](#_ENREF_17), [36](#_ENREF_36)]. Machin *et al*[[36](#_ENREF_36)] showed that consuming a high dairy diet (non-fat) for 4 weeks reduced central blood pressure and cfPWV compared with a high fruit diet. The relationship we observed whereby an increase in LPC 14:0, LPC 15:0 and LPC 16:1 was associated with an increase in central blood pressure may be explained by the proinflammatory and atherogenic properties of non-omega 3 polyunsaturated fatty acid enriched LPC[[37](#_ENREF_37)]. LPCs act on endothelial cells, smooth muscle cells, monocytes, macrophages and T-cells in a number of ways to inhibit endothelial relaxation and up-regulate production of inflammatory and adhesion molecules[[32](#_ENREF_32), [38](#_ENREF_38)]. Inflammation, measured by CRP, has been positively associated with blood pressure and development of hypertension[[39](#_ENREF_39), [40](#_ENREF_40)], which may explain our findings in the current study. As such, our results may not be due to the fatty acid composition per se but fatty acid metabolism and resulting lipid species. Previously total phospholipid C15:0 has been inversely associated with blood pressure and coronary heart disease[[41](#_ENREF_41)]. Although it remains unclear what the mechanism behind this finding is and this should be explored in the future.

Ruminant fatty acids C15:0 and C17:0 do not have the same physiological effects as other saturated fatty acids (although they have not been tested in isolation) and are not associated with increased risk of cardiovascular outcomes and may actually be protective[[42](#_ENREF_42), [43](#_ENREF_43)]. Dairy products also contain many other components such calcium, magnesium, phosphorus, potassium and bioactive peptides that may contribute to the cardio-protective effect of dairy consumption[[44-46](#_ENREF_44)]. In a four-way cross-over study it was shown that the calcium content of dairy products counteracts the fat content to attenuate the increase in total and LDL cholesterol, without reducing HDL cholesterol[[44](#_ENREF_44)]. The synergist effect of the different components in dairy products may explain why dairy consumption was not associated with any of the vascular measurements in the current study despite the observed association between the lipid species and these measurements.

Nestel *et al*[[21](#_ENREF_21)] showed that the phospholipid classes LPC and lysoalkylphosphatidylcholine were associated with measures of insulin sensitivity and insulin resistance. In addition, full fat dairy consumption was associated with phospholipid fatty acids C15:0 C16:1 and C18:1 n-7 but there was no relationship detected between dairy consumption and insulin sensitivity or resistance measures. This is similar to the findings of the present study whereby the change in dairy consumption was not associated with the change in central blood pressure or CCA IMT, but the change in a number of lipid species was associated with both the change in dairy intake and the change in central blood pressure and CCA IMT. This may be because lipid analysis provides a more objective measure of intake and is not limited by the measurement error associated with self-reported dietary intake, although it may be due to a lack of statistical power.

Limitations of this study are that it is observational and therefore causation cannot be established. In addition, just over half of the cohort were prescribed lipid lowering medication which may confound the results. Finally, this study comprises a small sample size and findings should be replicated in a larger cohort. We also did not have lipidomic data at 12-months but we assumed changes early in the observation period would be required in order see changes in IMT at 12-months.

In conclusion, in this cohort with type 1 and type 2 diabetes a number of serum lipid species that were associated with a change in full fat dairy consumption were also correlated with the 3-month change in central blood pressure and 12-month change in CCA IMT.

**Acknowledgements**

The authors of this study would like to acknowledge the contributions of study participants and the staff of the University of South Australia. We would like to thank Dr. Eva Pedersen for her help with data collection and providing nutritional counselling.

**COMMENTS**

***Background***

People with diabetes are at higher risk of cardiovascular disease than the general population. And poor diet is a leading contributor to the development of cardiovascular disease. At present the effect of dairy consumption on vascular health is unclear. In this study we aimed to determine lipid species that change in response to a change in dairy consumption. In addition, to investigate whether dairy associated lipid species are correlated with changes in measures of vascular structure and function.

***Research frontiers***

Measurement of dietary intake is challenging due to inaccurate reporting, which is well documented in people with diabetes. Previously it has been shown that serum lipid species of ruminant origin are correlated with dairy consumption. In this study, the authors investigated the association between dairy intake measured by dietary questionnaire and serum lipid species and vascular health.

***Innovations and breakthrough***

These analyses show that a change in the concentration of a number of serum lipid species (LPC 14:0, LPC 15:0, LPC 16:1, PC 29:0 PC 30:0, PC 31:0, CE 14:0), previously shown to be correlated with dairy consumption, were associated with a change in full fat dairy consumption. One or more of these lipid species were positively associated with the 3-month change in central blood pressure and 12-month change in CCA IMT in this cohort with type 1 and type 2 diabetes.

***Applications***

Due to the observational nature of this research these findings are hypothesis generating and should be confirmed in the future.

***Terminology***

Common carotid artery intima media thickness (CCA IMT) is visualized using B mode ultrasound. The intima-media complex is the area of tissue starting at the luminal edge of the artery and ending at the boundary between the media and the adventitia. CCA IMT is a measure of early atherosclerosis. Augmentation index and carotid femoral pulse wave velocity are non-invasive measures of arterial stiffness.

***Peer-review***

In the manuscript, the authors conducted a subanalysis of a previous randomized trial addressing the role of diary intake on vascular function and blood pressure parameters.

They documented a significant relationship between blood pressure and augmentation index and certain lipid parameters. The study is well conducted with a huge number of parameters analysed and the results are intriguing.

**References**

1 **Shaw JE**, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. *Diabetes Res Clin Pract* 2010; **87**: 4-14 [PMID: 19896746 DOI: 10.1016/j.diabres.2009.10.007]

2 **Carson AP**, Tanner RM, Yun H, Glasser SP, Woolley JM, Thacker EL, Levitan EB, Farkouh ME, Rosenson RS, Brown TM, Howard G, Safford MM, Muntner P. Declines in coronary heart disease incidence and mortality among middle-aged adults with and without diabetes. *Ann Epidemiol* 2014; **24**: 581-7 [PMID: 24970491 DOI: 10.1016/j.annepidem.2014.05.007]

3 **Juutilainen A**, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Similarity of the impact of type 1 and type 2 diabetes on cardiovascular mortality in middle-aged subjects. *Diabetes Care* 2008; **31**: 714-719 [PMID: 8083789 DOI: 10.2337/dc07-2124]

4 **Lind M**, Svensson A-M, Kosiborod M, Gudbjörnsdottir S, Pivodic A, Wedel H, Dahlqvist S, Clements M, Rosengren A. Glycemic Control and Excess Mortality in Type 1 Diabetes. *N Engl J Med* 2014; **371**: 1972-1982 [PMID: 25409370 DOI: 10.1056/NEJMoa1408214]

5 **Harding JL**, Shaw JE, Peeters A, Guiver T, Davidson S, Magliano DJ. Mortality Trends Among People With Type 1 and Type 2 Diabetes in Australia: 1997–2010. *Diabetes Care* 2014; **37**: 2579-2586 [PMID: 24947787 DOI: 10.2337/dc14-0096]

6 **Forouzanfar MH**, Alexander L, Anderson HR, Bachman VF, Biryukov S, Brauer M, Burnett R, Casey D, Coates MM, Cohen A, Delwiche K, Estep K, Frostad JJ, Kc A, Kyu HH, Moradi-Lakeh M, Ng M, Slepak EL, Thomas BA, Wagner J, Aasvang GM, Abbafati C, Ozgoren AA, Abd-Allah F, Abera SF, Aboyans V, Abraham B, Abraham JP, Abubakar I, Abu-Rmeileh NME, Aburto TC, Achoki T, Adelekan A, Adofo K, Adou AK, Adsuar JC, Afshin A, Agardh EE, Al Khabouri MJ, Al Lami FH, Alam SS, Alasfoor D, Albittar MI, Alegretti MA, Aleman AV, Alemu ZA, Alfonso-Cristancho R, Alhabib S, Ali R, Ali MK, Alla F, Allebeck P, Allen PJ, Alsharif U, Alvarez E, Alvis-Guzman N, Amankwaa AA, Amare AT, Ameh EA, Ameli O, Amini H, Ammar W, Anderson BO, Antonio CAT, Anwari P, Cunningham SA, Arnlöv J, Arsenijevic VSA, Artaman A, Asghar RJ, Assadi R, Atkins LS, Atkinson C, Avila MA, Awuah B, Badawi A, Bahit MC, Bakfalouni T, Balakrishnan K, Balalla S, Balu RK, Banerjee A, Barber RM, Barker-Collo SL, Barquera S, Barregard L, Barrero LH, Barrientos-Gutierrez T, Basto-Abreu AC, Basu A, Basu S, Basulaiman MO, Ruvalcaba CB, Beardsley J, Bedi N, Bekele T, Bell ML, Benjet C, Bennett DA, Benzian H, Bernabé E, Beyene TJ, Bhala N, Bhalla A, Bhutta ZA, Bikbov B, Abdulhak AAB, Blore JD, Blyth FM, Bohensky MA, Başara BB, Borges G, Bornstein NM, Bose D, Boufous S, Bourne RR, Brainin M, Brazinova A, Breitborde NJ, Brenner H, Briggs ADM, Broday DM, Brooks PM, Bruce NG, Brugha TS, Brunekreef B, Buchbinder R, Bui LN, Bukhman G, Bulloch AG, Burch M, Burney PGJ, Campos-Nonato IR, Campuzano JC, Cantoral AJ, Caravanos J, Cárdenas R, Cardis E, Carpenter DO, Caso V, Castañeda-Orjuela CA, Castro RE, Catalá-López F, Cavalleri F, Çavlin A, Chadha VK, Chang J-c, Charlson FJ, Chen H, Chen W, Chen Z, Chiang PP, Chimed-Ochir O, Chowdhury R, Christophi CA, Chuang T-W, Chugh SS, Cirillo M, Claßen TKD, Colistro V, Colomar M, Colquhoun SM, Contreras AG, Cooper C, Cooperrider K, Cooper LT, Coresh J, Courville KJ, Criqui MH, Cuevas-Nasu L, Damsere-Derry J, Danawi H, Dandona L, Dandona R, Dargan PI, Davis A, Davitoiu DV, Dayama A, de Castro EF, De la Cruz-Góngora V, De Leo D, de Lima G, Degenhardt L, del Pozo-Cruz B, Dellavalle RP, Deribe K, Derrett S, Jarlais DCD, Dessalegn M, deVeber GA, Devries KM, Dharmaratne SD, Dherani MK, Dicker D, Ding EL, Dokova K, Dorsey ER, Driscoll TR, Duan L, Durrani AM, Ebel BE, Ellenbogen RG, Elshrek YM, Endres M, Ermakov SP, Erskine HE, Eshrati B, Esteghamati A, Fahimi S, Faraon EJA, Farzadfar F, Fay DFJ, Feigin VL, Feigl AB, Fereshtehnejad S-M, Ferrari AJ, Ferri CP, Flaxman AD, Fleming TD, Foigt N, Foreman KJ, Paleo UF, Franklin RC, Gabbe B, Gaffikin L, Gakidou E, Gamkrelidze A, Gankpé FG, Gansevoort RT, García-Guerra FA, Gasana E, Geleijnse JM, Gessner BD, Gething P, Gibney KB, Gillum RF, Ginawi IAM, Giroud M, Giussani G, Goenka S, Goginashvili K, Dantes HG, Gona P, de Cosio TG, González-Castell D, Gotay CC, Goto A, Gouda HN, Guerrant RL, Gugnani HC, Guillemin F, Gunnell D, Gupta R, Gupta R, Gutiérrez RA, Hafezi-Nejad N, Hagan H, Hagstromer M, Halasa YA, Hamadeh RR, Hammami M, Hankey GJ, Hao Y, Harb HL, Haregu TN, Haro JM, Havmoeller R, Hay SI, Hedayati MT, Heredia-Pi IB, Hernandez L, Heuton KR, Heydarpour P, Hijar M, Hoek HW, Hoffman HJ, Hornberger JC, Hosgood HD, Hoy DG, Hsairi M, Hu G, Hu H, Huang C, Huang JJ, Hubbell BJ, Huiart L, Husseini A, Iannarone ML, Iburg KM, Idrisov BT, Ikeda N, Innos K, Inoue M, Islami F, Ismayilova S, Jacobsen KH, Jansen HA, Jarvis DL, Jassal SK, Jauregui A, Jayaraman S, Jeemon P, Jensen PN, Jha V, Jiang F, Jiang G, Jiang Y, Jonas JB, Juel K, Kan H, Roseline SSK, Karam NE, Karch A, Karema CK, Karthikeyan G, Kaul A, Kawakami N, Kazi DS, Kemp AH, Kengne AP, Keren A, Khader YS, Khalifa SEAH, Khan EA, Khang Y-H, Khatibzadeh S, Khonelidze I, Kieling C, Kim D, Kim S, Kim Y, Kimokoti RW, Kinfu Y, Kinge JM, Kissela BM, Kivipelto M, Knibbs LD, Knudsen AK, Kokubo Y, Kose MR, Kosen S, Kraemer A, Kravchenko M, Krishnaswami S, Kromhout H, Ku T, Defo BK, Bicer BK, Kuipers EJ, Kulkarni C, Kulkarni VS, Kumar GA, Kwan GF, Lai T, Balaji AL, Lalloo R, Lallukka T, Lam H, Lan Q, Lansingh VC, Larson HJ, Larsson A, Laryea DO, Lavados PM, Lawrynowicz AE, Leasher JL, Lee J-T, Leigh J, Leung R, Levi M, Li Y, Li Y, Liang J, Liang X, Lim SS, Lindsay MP, Lipshultz SE, Liu S, Liu Y, Lloyd BK, Logroscino G, London SJ, Lopez N, Lortet-Tieulent J, Lotufo PA, Lozano R, Lunevicius R, Ma J, Ma S, Machado VMP, MacIntyre MF, Magis-Rodriguez C, Mahdi AA, Majdan M, Malekzadeh R, Mangalam S, Mapoma CC, Marape M, Marcenes W, Margolis DJ, Margono C, Marks GB, Martin RV, Marzan MB, Mashal MT, Masiye F, Mason-Jones AJ, Matsushita K, Matzopoulos R, Mayosi BM, Mazorodze TT, McKay AC, McKee M, McLain A, Meaney PA, Medina C, Mehndiratta MM, Mejia-Rodriguez F, Mekonnen W, Melaku YA, Meltzer M, Memish ZA, Mendoza W, Mensah GA, Meretoja A, Mhimbira FA, Micha R, Miller TR, Mills EJ, Misganaw A, Mishra S, Ibrahim NM, Mohammad KA, Mokdad AH, Mola GL, Monasta L, Hernandez JCM, Montico M, Moore AR, Morawska L, Mori R, Moschandreas J, Moturi WN, Mozaffarian D, Mueller UO, Mukaigawara M, Mullany EC, Murthy KS, Naghavi M, Nahas Z, Naheed A, Naidoo KS, Naldi L, Nand D, Nangia V, Narayan KMV, Nash D, Neal B, Nejjari C, Neupane SP, Newton CR, Ngalesoni FN, de Dieu Ngirabega J, Nguyen G, Nguyen NT, Nieuwenhuijsen MJ, Nisar MI, Nogueira JR, Nolla JM, Nolte S, Norheim OF, Norman RE, Norrving B, Nyakarahuka L, Oh I-H, Ohkubo T, Olusanya BO, Omer SB, Opio JN, Orozco R, Pagcatipunan Jr RS, Pain AW, Pandian JD, Panelo CIA, Papachristou C, Park E-K, Parry CD, Caicedo AJP, Patten SB, Paul VK, Pavlin BI, Pearce N, Pedraza LS, Pedroza A, Stokic LP, Pekericli A, Pereira DM, Perez-Padilla R, Perez-Ruiz F, Perico N, Perry SAL, Pervaiz A, Pesudovs K, Peterson CB, Petzold M, Phillips MR, Phua HP, Plass D, Poenaru D, Polanczyk GV, Polinder S, Pond CD, Pope CA, Pope D, Popova S, Pourmalek F, Powles J, Prabhakaran D, Prasad NM, Qato DM, Quezada AD, Quistberg DAA, Racapé L, Rafay A, Rahimi K, Rahimi-Movaghar V, Rahman SU, Raju M, Rakovac I, Rana SM, Rao M, Razavi H, Reddy KS, Refaat AH, Rehm J, Remuzzi G, Ribeiro AL, Riccio PM, Richardson L, Riederer A, Robinson M, Roca A, Rodriguez A, Rojas-Rueda D, Romieu I, Ronfani L, Room R, Roy N, Ruhago GM, Rushton L, Sabin N, Sacco RL, Saha S, Sahathevan R, Sahraian MA, Salomon JA, Salvo D, Sampson UK, Sanabria JR, Sanchez LM, Sánchez-Pimienta TG, Sanchez-Riera L, Sandar L, Santos IS, Sapkota A, Satpathy M, Saunders JE, Sawhney M, Saylan MI, Scarborough P, Schmidt JC, Schneider IJC, Schöttker B, Schwebel DC, Scott JG, Seedat S, Sepanlou SG, Serdar B, Servan-Mori EE, Shaddick G, Shahraz S, Levy TS, Shangguan S, She J, Sheikhbahaei S, Shibuya K, Shin HH, Shinohara Y, Shiri R, Shishani K, Shiue I, Sigfusdottir ID, Silberberg DH, Simard EP, Sindi S, Singh A, Singh GM, Singh JA, Skirbekk V, Sliwa K, Soljak M, Soneji S, Søreide K, Soshnikov S, Sposato LA, Sreeramareddy CT, Stapelberg NJC, Stathopoulou V, Steckling N, Stein DJ, Stein MB, Stephens N, Stöckl H, Straif K, Stroumpoulis K, Sturua L, Sunguya BF, Swaminathan S, Swaroop M, Sykes BL, Tabb KM, Takahashi K, Talongwa RT, Tandon N, Tanne D, Tanner M, Tavakkoli M, Te Ao BJ, Teixeira CM, Téllez Rojo MM, Terkawi AS, Texcalac-Sangrador JL, Thackway SV, Thomson B, Thorne-Lyman AL, Thrift AG, Thurston GD, Tillmann T, Tobollik M, Tonelli M, Topouzis F, Towbin JA, Toyoshima H, Traebert J, Tran BX, Trasande L, Trillini M, Trujillo U, Dimbuene ZT, Tsilimbaris M, Tuzcu EM, Uchendu US, Ukwaja KN, Uzun SB, van de Vijver S, Van Dingenen R, van Gool CH, van Os J, Varakin YY, Vasankari TJ, Vasconcelos AMN, Vavilala MS, Veerman LJ, Velasquez-Melendez G, Venketasubramanian N, Vijayakumar L, Villalpando S, Violante FS, Vlassov VV, Vollset SE, Wagner GR, Waller SG, Wallin MT, Wan X, Wang H, Wang J, Wang L, Wang W, Wang Y, Warouw TS, Watts CH, Weichenthal S, Weiderpass E, Weintraub RG, Werdecker A, Wessells KR, Westerman R, Whiteford HA, Wilkinson JD, Williams HC, Williams TN, Woldeyohannes SM, Wolfe CDA, Wong JQ, Woolf AD, Wright JL, Wurtz B, Xu G, Yan LL, Yang G, Yano Y, Ye P, Yenesew M, Yentür GK, Yip P, Yonemoto N, Yoon S-J, Younis MZ, Younoussi Z, Yu C, Zaki ME, Zhao Y, Zheng Y, Zhou M, Zhu J, Zhu S, Zou X, Zunt JR, Lopez AD, Vos T, Murray CJ. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. The *Lancet* 2015; **386**: 2287-323 [PMID: 27733284 DOI: 10.1016/S0140-6736(15)00128-2]

7 **Iqbal R**, Anand S, Ounpuu S, Islam S, Zhang X, Rangarajan S, Chifamba J, Al-Hinai A, Keltai M, Yusuf S, on behalf of the INTERHEART Study Investigators. Dietary Patterns and the Risk of Acute Myocardial Infarction in 52 Countries: Results of the INTERHEART Study. *Circulation* 2008; **118**: 1929-1937 [PMID: 18936332 DOI: 10.1161/circulationaha.107.738716]

8 **Brunner EJ**, Mosdøl A, Witte DR, Martikainen P, Stafford M, Shipley MJ, Marmot MG. Dietary patterns and 15-y risks of major coronary events, diabetes, and mortality. *Am J Clin Nutr* 2008; **87**: 1414-1421 [PMID: 18469266]

9 **Qin L-Q**, Xu J-Y, Han S-F, Zhang Z-L, Zhao Y-Y, Szeto IM. Dairy consumption and risk of cardiovascular disease: an updated meta‐analysis of prospective cohort studies. *Asia Pac J Clin Nutr* 2015; **24**: 90-100 [PMID: 25740747]

10 **Mozaffarian D**. Dietary and Policy Priorities for Cardiovascular Disease, Diabetes, and Obesity A Comprehensive Review. *Circulation* 2016; **133**: 187-225 [PMID: 26746178 DOI: 10.1161/CIRCULATIONAHA.115.018585]

11 **Vlachopoulos C**, Aznaouridis K, O'Rourke MF, Safar ME, Baou K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. *Eur Heart J* 2010; **31**: 1865-1871 [PMID: 197424 DOI: 10.1093/eurheartj/ehq024]

12 **Ben-Shlomo Y**, Spears M, Boustred C, May M, Anderson SG, Benjamin EJ, Boutouyrie P, Cameron J, Chen CH, Cruickshank JK, Hwang SJ, Lakatta EG, Laurent S, Maldonado J, Mitchell GF, Najjar SS, Newman AB, Ohishi M, Pannier B, Pereira T, Vasan RS, Shokawa T, Sutton-Tyrell K, Verbeke F, Wang KL, Webb DJ, Hansen TW, Zoungas S, McEniery CM, Cockcroft JR, Wilkinson IB. Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects. *J Am Coll Cardiol* 2014; **63**: 636-46 [PMID: 24239664 DOI: 10.1016/j.jacc.2013.09.063]

13 **Schwartz SM**, deBlois D, O’Brien ERM. The Intima: Soil for Atherosclerosis and Restenosis. *Circ Res* 1995; **77**: 445-465 [PMID: 7641318 DOI: 10.1161/01.res.77.3.445]

14 **Lorenz MW**, Polak JF, Kavousi M, Mathiesen EB, Völzke H, Tuomainen T-P, Sander D, Plichart M, Catapano AL, Robertson CM, Kiechl S, Rundek T, Desvarieux M, Lind L, Schmid C, DasMahapatra P, Gao L, Ziegelbauer K, Bots ML, Thompson SG. Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data. *The Lancet* 2012; **379**: 2053-2062 [PMID: 22541275 DOI: 10.1016/s0140-6736(12)60441-3]

15 **Recio-Rodriguez J**, Gomez-Marcos M, Patino-Alonso M-C, Sanchez A, Agudo-Conde C, Maderuelo-Fernandez J, Garcia-Ortiz L, on behalf of the EVIDENT Group. Association between fat amount of dairy products with pulse wave velocity and carotid intima-media thickness in adults. *Nutr J* 2014; **13**: 37 [PMID: 24761762 DOI: 10.1186/1475-2891-13-37]

16 **Ivey KL**, Lewis JR, Hodgson JM, Zhu K, Dhaliwal SS, Thompson PL, Prince RL. Association between yogurt, milk, and cheese consumption and common carotid artery intima-media thickness and cardiovascular disease risk factors in elderly women. *Am J Clin Nutr* 2011; **94**: 234-9 [PMID: 21613553 DOI: 10.3945/ajcn.111.014159]

17 **Crichton GE**, Elias MF, Dore GA, Abhayaratna WP, Robbins MA. Relations Between Dairy Food Intake and Arterial Stiffness. *Hypertension* 2012; **59**: 1044-1051 [PMID: 22431583 DOI: 10.1161/hypertensionaha.111.190017]

18 **Livingstone KM**, Lovegrove JA, Cockcroft JR, Elwood PC, Pickering JE, Givens DI. Does Dairy Food Intake Predict Arterial Stiffness and Blood Pressure in Men?: Evidence from the Caerphilly Prospective Study. *Hypertension* 2013; **61**: 42-47 [PMID: 23150503 DOI: 10.1161/hypertensionaha.111.00026]

19 **Petersen KS**, Keogh JB, Meikle PJ, Garg ML, Clifton PM. Dietary predictors of arterial stiffness in a cohort with type 1 and type 2 diabetes. *Atherosclerosis* 2015; **238**: 175-181 [PMID: 25528424 DOI: 10.1016/j.atherosclerosis.2014.12.012]

20 **Sallé A**, Ryan M, Ritz P. Underreporting of Food Intake in Obese Diabetic and Nondiabetic Patients. *Diabetes Care* 2006; **29**: 2726-2727 [PMID: 17130213 DOI: 10.2337/dc06-1582]

21 **Nestel PJ**, Straznicky N, Mellett NA, Wong G, De Souza DP, Tull DL, Barlow CK, Grima MT, Meikle PJ. Specific plasma lipid classes and phospholipid fatty acids indicative of dairy food consumption associate with insulin sensitivity. *Am J Clin Nutr* 2014; **99**: 46-53 [PMID: 24153346 DOI: 10.3945/ajcn.113.071712]

22 **Petersen KS**, Clifton PM, Blanch N, Keogh JB. Effect of improving dietary quality on carotid intima media thickness in subjects with type 1 and type 2 diabetes: a 12-mo randomized controlled trial. *Am J Clin Nutr* 2015; **102**: 771-779 [PMID: 26354542 DOI: 10.3945/ajcn.115.112151]

23 **Weir JM**, Wong G, Barlow CK, Greeve MA, Kowalczyk A, Almasy L, Comuzzie AG, Mahaney MC, Jowett JBM, Shaw J, Curran JE, Blangero J, Meikle PJ. Plasma lipid profiling in a large population-based cohort. *J Lipid Res* 2013; **54**: 2898-2908 [PMID: 23868910 DOI: 10.1194/jlr.P035808]

24 **Hodge A**, Patterson AJ, Brown WJ, Ireland P, Giles G. The Anti Cancer Council of Victoria FFQ: relative validity of nutrient intakes compared with weighed food records in young to middle-aged women in a study of iron supplementation. *Aust N Z J Public Health* 2000; **24**: 576-583 [PMID: 11215004 DOI: 10.1111/j.1467-842X.2000.tb00520.x]

25 **Petersen KS**, Smith JM, Clifton PM, Keogh JB. Dietary intake in adults with type 1 and type 2 diabetes: validation of the Dietary Questionnaire for Epidemiological Studies version 2 FFQ against a 3-d weighed food record and 24-h urinalysis. *Br J Nutr* 2015; **114**: 2056-2063 [PMID: 26423654 DOI: 10.1017/S0007114515003748]

26 **Touboul P**, Hennerici M, Meairs S, Adams H, Amarenco P, Bornstein N, Csiba L, Desvarieux M, Ebrahim S, Hernandez Hernandez R, Jaff M, Kownator S, Naqvi T, Prati P, Rundek T, Sitzer M, Schminke U, Tardif JC, Taylor A, Vicaut E, Woo KS. Mannheim carotid intima-media thickness and plaque consensus (2004-2006-2011). An update on behalf of the advisory board of the 3rd, 4th and 5th watching the risk symposia, at the 13th, 15th and 20th European Stroke Conferences, Mannheim, Germany, 2004, Brussels, Belgium, 2006, and Hamburg, Germany, 2011. *Cerebrovasc Dis* 2012; **34**: 290-6 [PMID: PMID: 23128470 DOI: 10.1159/000343145]

27 **Wolk A**, Vessby B, Ljung H, Barrefors P. Evaluation of a biological marker of dairy fat intake. *Am J Clin Nutr* 1998; **68**: 291-5 [PMID: 9701185]

28 **Wolk A**, Furuheim M, Vessby B. Fatty Acid Composition of Adipose Tissue and Serum Lipids Are Valid Biological Markers Of Dairy Fat Intake in Men. *J Nutr* 2001; **131**: 828-833 [PMID: 11238766]

29 **Micha R**, King IB, Lemaitre RN, Rimm EB, Sacks F, Song X, Siscovick DS, Mozaffarian D. Food sources of individual plasma phospholipid trans fatty acid isomers: the Cardiovascular Health Study. *Am J Clin Nutr* 2010; **91**: 883-893 [PMID: 20219966 DOI: 10.3945/ajcn.2009.28877]

30 **Benjamini Y**, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J. Roy. Statist. Soc. Ser. B 1995; **57**: 289-300 [PMID: DOI: 10.2307/2346101]

31 **Sato H**, Kato R, Isogai Y, Saka G-i, Ohtsuki M, Taketomi Y, Yamamoto K, Tsutsumi K, Yamada J, Masuda S, Ishikawa Y, Ishii T, Kobayashi T, Ikeda K, Taguchi R, Hatakeyama S, Hara S, Kudo I, Itabe H, Murakami M. Analyses of Group III Secreted Phospholipase A2 Transgenic Mice Reveal Potential Participation of This Enzyme in Plasma Lipoprotein Modification, Macrophage Foam Cell Formation, and Atherosclerosis. *J Biol Chem* 2008; **283**: 33483-33497 [PMID: 18801741 DOI: 10.1074/jbc.M804628200]

32 **Takayuki M**, Tsuneo K, Katsuo K. Role of Lysophosphatidylcholine (LPC) in Atherosclerosis. *Curr Med Chem* 2007; **14**: 3209-3220 [DOI: 10.2174/092986707782793899]

33 **Nestel PJ**, Mellett N, Pally S, Wong G, Barlow CK, Croft K, Mori TA, Meikle PJ. Effects of low-fat or full-fat fermented and non-fermented dairy foods on selected cardiovascular biomarkers in overweight adults. *Br J Nutr* 2013; **110**: 2242-2249 [PMID: 23756569 DOI: 10.1017/S0007114513001621]

34 **Bobryshev YV**, Lord RSA, Golovanova NK, Gracheva EV, Zvezdina ND, Sadovskaya VL, Prokazova NV. Incorporation and localisation of ganglioside GM3 in human intimal atherosclerotic lesions. *Biochim Biophys Acta* 1997; **1361**: 287-294 [PMID: 9375803 DOI: 10.1016/S0925-4439(97)00044-6]

35 **Inokuchi JI**. GM3 and diabetes. *Glycoconj J* 2014; **31**: 193-197 [PMID: DOI: 10.1007/s10719-013-9516-4]

36 **Machin DR**, Park W, Alkatan M, Mouton M, Tanaka H. Effects of non-fat dairy products added to the routine diet on vascular function: A randomized controlled crossover trial. *Nutr Metab Cardiovasc Dis* **25**: 364-369 [PMID: 25770758 DOI: 10.1016/j.numecd.2015.01.005]

37 **Akerele OA**, Cheema SK. Fatty acyl composition of lysophosphatidylcholine is important in atherosclerosis. *Medical Hypotheses* 2015; **85**: 754-760 [PMID: 26604024 DOI: 10.1016/j.mehy.2015.10.013]

38 **Schmitz G**, Ruebsaamen K. Metabolism and atherogenic disease association of lysophosphatidylcholine. *Atherosclerosis* 2010; **208**: 10-18 [PMID: 19570538 DOI: 10.1016/j.atherosclerosis.2009.05.029]

39 **Emerging Risk Factors Collaboration**. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. *The Lancet* 2010; **375**: 132 [PMID: 20031199 DOI: 10.1016/S0140-6736(09)61717-7]

40 **Sesso HD**, Wang L, Buring JE, Ridker PM, Gaziano JM. Comparison of Interleukin-6 and C-Reactive Protein for the Risk of Developing Hypertension in Women. *Hypertension* 2007; **49**: 304-310 [PMID: 17159088 DOI: 10.1161/01.HYP.0000252664.24294.ff]

41 **de Oliveira Otto MC**, Nettleton JA, Lemaitre RN, M. Steffen L, Kromhout D, Rich SS, Y. Tsai M, Jacobs DR, Mozaffarian D. Biomarkers of Dairy Fatty Acids and Risk of Cardiovascular Disease in the Multi‐Ethnic Study of Atherosclerosis. *J Am Heart Assoc* 2013; **2**: e000092 [PMID: 23868191 DOI: 10.1161/JAHA.113.000092]

42 **Dawczynski C**, Kleber ME, März W, Jahreis G, Lorkowski S. Saturated fatty acids are not off the hook. *Nutr Metab Cardiovasc Dis* 2015; **25**: 1071-1078 [PMID: 26626084 DOI: 10.1016/j.numecd.2015.09.010]

43 **Khaw K-T**, Friesen MD, Riboli E, Luben R, Wareham N. Plasma Phospholipid Fatty Acid Concentration and Incident Coronary Heart Disease in Men and Women: The EPIC-Norfolk Prospective Study. *PLoS Med* 2012; **9**: e1001255 [PMID: 22802735 DOI: 10.1371/journal.pmed.1001255]

44 **Lorenzen JK**, Jensen SK, Astrup A. Milk minerals modify the effect of fat intake on serum lipid profile: results from an animal and a human short-term study. *Br J Nutr* 2014; **111**: 1412-1420 [PMID: 24267180 DOI: 10.1017/S0007114513003826]

45 **FitzGerald RJ**, Murray BA, Walsh DJ. Hypotensive Peptides from Milk Proteins. *J Nutr* 2004; **134**: 980S-988S

46 **Appel LJ**, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, Bray GA, Vogt TM, Cutler JA, Windhauser MM, Lin P-H, Karanja N, Simons-Morton D, McCullough M, Swain J, Steele P, Evans MA, Miller ER, Harsha DW. A Clinical trial of the effects of dietary patterns on blood pressure. *N Engl J Med* 1997; **336**: 1117-1124 [PMID: 9099655 DOI: 10.1056/NEJM199704173361601]

**P-Reviewer:** Neves MF, van Bilsen M, Verdoia M **S-Editor:** Gong ZM

**L-Editor:** **E-Editor:**

**Table 1 Baseline characteristics of the participants *n* (%)**

|  |  |
| --- | --- |
| **Characteristic** | **Cohort (*n* = 108)** |
| Age (yr) | 58 ± 14 |
| Weight (kg) | 96.2 ± 20.6 |
| BMI (kg/m2) | 32.6 ± 6.4 |
| Sex |  |
| Female | 40 (37) |
| Male | 68 (63) |
| Diabetes type |  |
| Type 1 | 14 (13) |
| Type 2 | 94 (87) |
| Time since diabetes diagnosis (yr) |  |
| Type 1 | 21 ± 13 |
| Type 2 | 8 ± 7 |
| Smoking status |  |
| Never smoked | 56 (52) |
| Past smoker | 47 (43) |
| Current smoker | 5 (5) |
| Smoking pack years (years)Ϯ | 10.5 ± 16.3 |
| Prescribed anti-hypertensive medication | 66 (61) |
| Prescribed lipid lowering medication | 61 (57) |
| Diabetes treatment |  |
| None | 22 (20) |
| OHA | 49 (46) |
| Insulin | 16 (15) |
| OHA + Insulin | 21 (19) |
| Presence of Microalbuminuria1 | 14 (13) |
| HbA1c | 7.1 ± 1.2 |

All values are mean ± SD or n (%) where specified;ϮSmoking pack years = number packs (25cigarettes)/day x number years smoked; 1Albumin:creatinine > 2.5 for men and > 3.5 for women. BMI: body mass index; OHA: oral hypoglycaemic agents.

**Table 2 Dietary intake measured using a food frequency questionnaire**

|  |  |  |  |
| --- | --- | --- | --- |
| **Intake (g/d)** | **Cohort (*n* = 108)** | | ***P* value for change** |
| **Baseline** | **3 months** |
| Total dairy1 | 432 ± 218 | 434 ± 198 | 0.90 |
| Total full fat dairy1 | 113 ± 201 | 94 ± 162 | 0.16 |
| Milk | 349 ± 201 | 345 ± 188 | 0.78 |
| Yoghurt | 55 ± 65 | 68 ± 76 | 0.031 |
| Cheese | 14 ± 12 | 11 ± 10 | 0.005 |
| Butter | 2 ± 6 | 1 ± 4 | 0.051 |
| Ice-cream | 11 ± 18 | 9 ± 10 | 0.063 |

1Includes milk, yoghurt, cheese, butter, ice-cream. All values are mean ± SD; Data analysed using paired samples *t*-test.

**Table 3 Spearman’s correlation of the change in total full fat dairy (milk, yoghurt, cheese, butter, ice-cream) with change in lipid species**

|  |  |  |
| --- | --- | --- |
| **Change in lipid species** | **rho value** | ***P* value** |
| LPC 14:0 | 0.25 | 0.01 |
| LPC 15:0 | 0.21 | 0.03 |
| LPC 16:1 | 0.22 | 0.02 |
| PC 29:0 | 0.22 | 0.02 |
| PC 30:0 | 0.23 | 0.02 |
| PC 31:0 | 0.19 | 0.049 |
| CE 14:0 | 0.24 | 0.01 |


**Table 4 Anthropometric measures, blood pressure, biochemistry and vascular measurements at baseline and follow-up**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Baseline** | **3 months** | ***P* value for change** |
| Weight (kg) | 96.2 ± 20.6 | 95.9 ± 20.6 | 0.40 |
| Peripheral systolic blood pressure (kPa) | 16.9 ± 2.0 | 16.9 ± 1.9 | 0.75 |
| Peripheral diastolic blood pressure (kPa) | 9.4 ± 1.3 | 9.4 ± 1.3 | 0.69 |
| Peripheral mean arterial pressure (kPa) | 12 ± 1.3 | 12 ± 1.3 | 0.69 |
| Peripheral pulse pressure (kPa) | 7.4 ± 1.3 | 7.4 ± 1.7 | 0.93 |
| Central systolic blood pressure (kPa) | 16.8 ± 1.3 | 16.1 ± 1.9 | 0.004 |
| Central diastolic blood pressure (kPa) | 10.9 ± 1.3 | 10.5 ± 1.2 | 0.002 |
| Central mean arterial pressure (kPa) | 13.2 ± 1.5 | 12.8 ± 1.3 | 0.002 |
| Central pulse pressure (kPa) | 5.9 ± 1.7 | 5.8 ± 1.7 | 0.09 |
| Central augmented pressure (kPa) | 1.2 ± 0.6 | 1.1 ± 0.8 | 0.07 |
| Augmentation index (%) | 19 ± 7 | 21 ± 12 | 0.005 |
| cfPWV (m/s) | 9.4 ± 1.7 | 9.4 ± 1.8 | 0.63 |
| Pulse transit time (m/s) | 60 ± 10 | 60 ± 9 | 0.95 |
| CCA-IMT (mm) | 0.72 ± 0.12 | 0.71 ± 0.121 | 0.002 |
| Total cholesterol (mmol/L) | 3.7 ± 1.0 | 3.7 ± 1.0 | 0.59 |
| HDL cholesterol (mmol/L) | 1.2 ± 0.3 | 1.2 ± 0.3 | 0.54 |
| LDL cholesterol (mmol/L) | 2.0 ± 0.8 | 2.0 ± 0.7 | 0.40 |
| Triglycerides (mmol/L) | 1.1 ± 0.9 | 1.1 ± 0.9 | 0.53 |
| Glucose (mmol/L) | 7.3 ± 2.9 | 7.3 ± 2.7 | 0.95 |
| High sensitivity C reactive protein (mg/L) | 2.5 ± 2.4 | 2.4 ± 2.4 | 0.80 |

1Follow-up was at 12 mo. All values are mean ± SD; Data analysed using paired samples *t*-test.

**Table 5 Spearman’s correlation between the absolute and percent change in dairy associated lipid species and the absolute and percent change in vascular measures**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Absolute change** | | **Percent change** |  |
|  | **rho value** | ***P* value** | **rho value** | ***P* value** |
| **Central systolic blood pressure** | | |  |  |
| LPC 14:0 | 0.30 | 0.007 | 0.28 | 0.01 |
| PC 30:0 | 0.28 | 0.010 | 0.31 | 0.004 |
| PC 31:0 | 0.20 | 0.07 | 0.22 | 0.046 |
| **Central diastolic blood pressure** | | |  |  |
| LPC 14:0 | 0.32 | 0.004 | 0.32 | 0.00 |
| LPC 15:0 | 0.23 | 0.04 | 0.22 | 0.046 |
| LPC 16:1 | 0.23 | 0.035 | 0.21 | 0.06 |
| PC 29:0 | 0.28 | 0.01 | 0.34 | 0.002 |
| PC 30:0 | 0.36 | 0.001 | 0.40 | 0.001 |
| PC 31:0 | 0.30 | 0.007 | 0.31 | 0.004 |
| **Central mean arterial pressure** | | |  |  |
| LPC 14:0 | 0.30 | 0.007 | 0.29 | 0.009 |
| PC 29:0 | 0.21 | 0.06 | 0.25 | 0.025 |
| PC 30:0 | 0.31 | 0.005 | 0.33 | 0.002 |
| PC 31:0 | 0.24 | 0.033 | 0.24 | 0.028 |
| **Augmentation index** | | |  |  |
| Nil significant |  |  |  |  |
| **cfPWV** |  |  |  |  |
| Nil significant |  |  |  |  |
| **CCA-IMT** |  |  |  |  |
| CE 14:0 | 0.22 | 0.02 | 0.23 | 0.02 |



**Figure 1 CONSORT diagram.**